Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The new COVID-19 variant NB.1.8.1, known as Nimbus, is causing concern due to its subtle symptoms and high transmission rate.

Mild side effects are common after COVID-19 vaccines and boosters. Learn more about how you can prevent and treat any uncomfortable symptoms.